OptimizeRx Corporation, a digital health technology company, provides various solutions to life sciences organizations, healthcare providers, and patients The company’s products and applications include financial messaging, a virtual patient support center that allows doctors and staff to access sample vouchers, co-pay coupons, and other patient support through their EMR and/or e-prescribe systems; and brand awareness and therapeutic support messaging services, such as brand awareness messages, reminder ads, and therapeutic support and unbranded messages.
infoOptimizeRx is a micro cap stock with a total market cap of 129.11M.
infoThey trade on the NASDAQ and had their IPO 15 years and 8 months ago.
infoOptimizeRx currently employs 109 people.
infoAs of Wednesday, Aug 23 2023, OptimizeRx’s share price is $7.76.
News Relating to OptimizeRx
Seeking Alpha
OptimizeRx Corporation (OPRX) Q2 2023 Earnings Call Transcript
Monday Aug 14 2023 at 18:54
OptimizeRx Corporation. (NASDAQ:OPRX ) Q2 2023 Earnings Conference Call August 14, 2023 4:30 PM ET Company Participants William Febbo – Chief Executive Officer Edward Stelmakh – Chief Financial and Operating Officer Stephen Silvestro – Chief Commercial Officer Marion Odence-Ford – General Counsel and Chief Compliance Officer Andrew D’Silva – Senior Vice President, Corporate Finance Conference Call Participants Ryan Daniels – William Blair Sean Dodge – RBC Capital Markets Eric Martinuzzi – Lake Street Operator Good afternoon, everyone.
GlobeNewsWire
OptimizeRx Sets Second Quarter 2023 Conference Call for August 14, 2023 at 4:30 p.m. ET
Monday Jul 31 2023 at 08:01
ROCHESTER, Mich., July 31, 2023 (GLOBE NEWSWIRE) — OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy will hold a conference call on Monday, August 14, 2023 at 4:30 p.m. Eastern Time to discuss its results for the second quarter and half year period ended June 30, 2023. The financial results will be issued in a press release prior to the call.
Seeking Alpha
OptimizeRx Aims For Growth After Swoon
Friday Jul 21 2023 at 13:47
OptimizeRx Corporation provides communication technologies between pharma firms, healthcare providers, and patients. The company has seen material operating headwinds as the U.S. healthcare industry exited the pandemic and FDA approvals slowed. Until we see improving operating metrics and faster FDA approvals, I’m Neutral [Hold] on OptimizeRx Corporation.
Seeking Alpha
OptimizeRx Corporation (OPRX) Q1 2023 Earnings Call Transcript
Wednesday May 10 2023 at 22:44
OptimizeRx Corporation (NASDAQ:OPRX ) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Will Febbo – Chief Executive Officer Ed Stelmakh – Chief Financial and Operating Officer Steve Silvestro – Chief Commercial Officer Marion Odence-Ford – General Counsel and Chief Compliance Officer Andrew D’Silva – Senior Vice President, Corporate Finance Conference Call Participants Jared Haase – William Blair Sean Dodge – RBC Stephanie Davis – SVB David Grossman – Stifel Neil Chatterji – B. Riley Max Michaels – Lake Street Capital Markets Operator Good afternoon, everyone.
Zacks Investment Research
OptimizeRx Corp. (OPRX) Reports Q1 Loss, Tops Revenue Estimates
Wednesday May 10 2023 at 18:59
OptimizeRx Corp. (OPRX) came out with a quarterly loss of $0.09 per share versus the Zacks Consensus Estimate of a loss of $0.08. This compares to loss of $0.01 per share a year ago.
Seeking Alpha
OptimizeRx Has A Good Growth Path Ahead
Monday Apr 03 2023 at 17:16
OptimizeRx Corporation is an interesting company with an investment thesis based on its ability to capture a large TAM, with customers being some of the largest pharma companies out there. The company’s financial position is robust and they have been able to grow its top line at a notable and impressive rate recently.
Zacks Investment Research
OptimizeRx Corp. (OPRX) Soars 7.2%: Is Further Upside Left in the Stock?
Wednesday Mar 15 2023 at 04:37
OptimizeRx Corp. (OPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
Benzinga
Top 5 Health Care Stocks Which Could Rescue Your Portfolio This Month – Cara Therapeutics (NASDAQ:CARA), AdaptHealth (NASDAQ:AHCO)
Tuesday Mar 14 2023 at 08:02
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Seeking Alpha
OptimizeRx Corporation (OPRX) Q4 2022 Earnings Call Transcript
Wednesday Mar 08 2023 at 22:23
OptimizeRx Corporation (NASDAQ:OPRX ) Q4 2022 Earnings Conference Call March 8, 2023 4:30 PM ET Company Participants Will Febbo – CEO Ed Stelmakh – CFO and COO Steve Silvestro – Chief Commercial Officer Conference Call Participants Ryan Daniels – William Blair Sean Dodge – RBC Capital Markets Stephanie Davis – SVB David Grossman – Stifel Neil Chatterji – B. Riley Eric Martinuzzi – Lake Street Operator Good afternoon everyone and thank you for joining OptimizeRx’s Fourth Quarter Fiscal 2022 Earnings Discussion.
Zacks Investment Research
OptimizeRx Corp. (OPRX) Q4 Earnings Beat Estimates
Wednesday Mar 08 2023 at 18:48
OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of 4.17% and 9.81%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research
Should You Buy OptimizeRx (OPRX) Ahead of Earnings?
Thursday Mar 02 2023 at 12:02
OptimizeRx (OPRX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
GlobeNewsWire
OptimizeRx Sets Fourth Quarter & Fiscal Year 2022 Conference Call for March 8, 2023 at 4:30 p.m. ET
Thursday Feb 23 2023 at 08:00
ROCHESTER, Mich., Feb. 23, 2023 (GLOBE NEWSWIRE) — OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, will hold a conference call on Wednesday, March 8, 2023 at 4:30 p.m. Eastern Time to discuss its results for the fourth quarter and fiscal year, ended December 31, 2022. The financial results will be issued in a press release prior to the call.
Zacks Investment Research
Strength Seen in OptimizeRx Corp. (OPRX): Can Its 10.1% Jump Turn into More Strength?
Thursday Jan 05 2023 at 07:32
OptimizeRx Corp. (OPRX) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.
GlobeNewsWire
OptimizeRx to Participate in Upcoming Investor Conferences
Monday Nov 28 2022 at 09:31
ROCHESTER, Mich., Nov. 28, 2022 (GLOBE NEWSWIRE) — OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, today announced that management will participate in the following upcoming investor conferences:
Seeking Alpha
OptimizeRx Corporation (OPRX) Q3 2022 Earnings Call Transcript
Wednesday Nov 09 2022 at 00:56
OptimizeRx Corporation (NASDAQ:OPRX ) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Will Febbo – Chief Executive Officer Ed Stelmakh – Chief Financial and Operating Officer Steve Silvestro – Chief Commercial Officer Marion Odence-Ford – General Counsel and Chief Compliance Officer Andrew D’Silva – Senior Vice President, Corporate Finance Conference Call Participants Jared Haase – William Blair Sean Dodge – RBC Capital Markets David Grossman – Stifel Joy Zhang – SVB Securities Eric Martinuzzi – Lake Street Capital Markets Marc Wiesenberger – B. Riley Securities Operator Good afternoon, everyone and thank you for joining OptimizeRx’s Third Quarter Fiscal 2022 Earnings Discussion.
Zacks Investment Research
OptimizeRx Corp. (OPRX) Tops Q3 Earnings Estimates
Tuesday Nov 08 2022 at 18:48
OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of 75% and 0.47%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewsWire
OptimizeRx Sets Third Quarter Fiscal 2022 Conference Call for Tuesday, November 8 at 4:30 p.m. ET
Wednesday Oct 19 2022 at 16:05
ROCHESTER, Mich., Oct. 19, 2022 (GLOBE NEWSWIRE) — OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, will hold a conference call on Tuesday, November 8, 2022, at 4:30 p.m. Eastern time to discuss its results for the third quarter, ended September 30, 2022. The financial results will be issued in a press release prior to the call.
Seeking Alpha
OptimizeRx: A Top Candidate For My Speculative ‘Bio Boom’ Portfolio
Wednesday Oct 12 2022 at 06:46
OptimizeRx has lost roughly 83% over the past twelve months despite showing impressive growth and profitability metrics. The market-wide sell-off is providing an opportunity to establish a position in OPRX. The company is expected to report double-digit growth over the next two years and hit around $95M in 2024, which is a ~2.85x forward price-to-sales.
Seeking Alpha
OptimizeRx Corporation (OPRX) CEO William Febbo on Q2 2022 Results – Earnings Call Transcript
Tuesday Aug 09 2022 at 21:50
OptimizeRx Corporation (NASDAQ:OPRX ) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants William Febbo – CEO and Director Ed Stelmakh – CFO and COO Stephen Silvestro – Chief Commercial Officer Conference Call Participants Ryan Daniels – William Blair Joy Zhang – SVB Securities Sean Dodge – RBC Capital Markets Eric Martinuzzi – Lake Street Marc Wiesenberger – B. Riley Securities Jeff Garro – Piper Sandler Operator Good afternoon, everyone.
Zacks Investment Research
OptimizeRx Corp. (OPRX) Misses Q2 Earnings and Revenue Estimates
Tuesday Aug 09 2022 at 20:19
OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of -60% and 18.26%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?
GlobeNewsWire
OptimizeRx Sets Second Quarter Fiscal 2022 Conference Call for Tuesday, August 9 at 4:30 p.m. ET
Thursday Jul 21 2022 at 07:30
ROCHESTER, Mich., July 21, 2022 (GLOBE NEWSWIRE) — OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on therapy, will hold a conference call on Tuesday, August 9, 2022, at 4:30 p.m. Eastern time to discuss its results for the second quarter, ended June 30, 2022. The financial results will be issued in a press release prior to the call.
Benzinga
SVB Leerink Sees ‘Cheaper Way’ To Pharma Digital Marketing With This Stock
Friday Jul 15 2022 at 15:23
SVB Leerink initiated coverage on OptimizeRx Corporation (NASDAQ: OPRX) with a buy rating and a price target of $38, implying an upside of 36%. The analysts say OptimizeRx is the largest EHR-embedded messaging network and enjoys a solid financial profile of 30%+ top-line growth.
Seeking Alpha
OptimizeRx: A Small-Cap Digital Health Technology Gem With Near-Term Inflection In Profitability
Monday Jun 27 2022 at 06:31
Large and growing TAM with industry tailwinds like digitalization supporting growth in demand for OptimizeRx’s solutions. Highly scalable operating model with more than sufficient network capacity to facilitate growth in the near term.
InvestorPlace
5 Small-Cap Stocks That Are Diamonds in the Rough
Thursday Jun 16 2022 at 12:27
Small-cap stocks are less liquid, more volatile, and have a lower market cap. But they also offer the opportunity for greater returns.
Seeking Alpha
OptimizeRx Corporation (OPRX) CEO William Febbo on Q1 2022 Results – Earnings Call Transcript
Wednesday May 04 2022 at 22:42
OptimizeRx Corporation (NASDAQ:OPRX ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants William Febbo – Chief Executive Officer Ed Stelmakh – Chief Financial Officer & Chief Operating Officer Andrew D’Silva – Senior Vice President of Corporate Finance Conference Call Participants Ryan Daniels – William Blair Sean Dodge – RBC Capital Markets Mark Wiesenberger – B. Riley Securities Max Michaelis – Lake Street Capital Markets Harvey Poppel – Poppel Operator Greetings.
Zacks Investment Research
OptimizeRx Corp. (OPRX) Reports Q1 Loss, Lags Revenue Estimates
Wednesday May 04 2022 at 19:34
OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of -200% and 0.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Seeking Alpha
OptimizeRx’s (OPRX) CEO William Febbo on Q4 2021 Results – Earnings Call Transcript
Thursday Feb 24 2022 at 22:12
OptimizeRx’s (OPRX) CEO William Febbo on Q4 2021 Results – Earnings Call Transcript
Zacks Investment Research
OptimizeRx Corp. (OPRX) Q4 Earnings and Revenues Beat Estimates
Thursday Feb 24 2022 at 19:16
OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of 22.22% and 1.07%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Zacks Investment Research
OptimizeRx Corp. (OPRX) Misses Q3 Earnings Estimates
Tuesday Nov 09 2021 at 20:35
OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of -30.77% and 8.78%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?
Seeking Alpha
OptimizeRx’s (OPRX) CEO William Febbo on Q3 2021 Results – Earnings Call Transcript
Tuesday Nov 09 2021 at 20:09
OptimizeRx’s (OPRX) CEO William Febbo on Q3 2021 Results – Earnings Call Transcript
OptimizeRx Bankruptcy Risk
The Altman Z-score is a formula that measures a company’s financial health and bankruptcy risk. It assigns a numerical score based on various financial ratios. The Z-score is divided into different zones. If the Z-score is above 2.99, it indicates a lower bankruptcy risk, classifying the company as ‘safe’ or ‘non-distressed’. If the score falls below 1.81, it suggests a higher risk, indicating potential financial distress or bankruptcy. The range between 1.81 and 2.99 is called the ‘gray zone’ or zone of ambiguity.
Learn more at Investopediaopen_in_new
OptimizeRx’s Altman Z-score is 14.26 which is in the safe zone. This indicates the company is financially stable and less likely to experience financial distress or bankruptcy.
Derived from SEC.GOV filing dataopen_in_new
OptimizeRx Insider Trading
Insider trading is when individuals employed by a company buy or sell its securities following legal procedures and regulations. Company executives, directors, and employees may be permitted to buy or sell shares if they follow specific rules, such as filing a Form 4 with the SEC within two business days.
Learn more at Investopediaopen_in_new
Over the last 3 months, there has been no insider trading in OptimizeRx.
Derived from SEC.GOV filing dataopen_in_new
Debt & Income Analysis
Income quality measures a company’s operating cash flow to net income ratio. It helps investors and analysts assess the sustainability of a company’s earnings. A high QIR indicates strong cash flows, while a low QIR may indicate non-operating activities driving net income.
Learn more at WallStreetPrepopen_in_new
OptimizeRx’s Income Quality of 0.01 is lower than its Industry Group of 0.59 (-98.3% lower)
OptimizeRx’s Income Quality of 0.01 is lower than its Major Industry Group of 0.42 (-97.6% lower)
OptimizeRx’s Income Quality of 0.01 is lower than its Sector of 0.5 (-98.0% lower)
Derived from SEC.GOV filing dataopen_in_new
Current ratio measures a company’s ability to pay off short-term debt with its current assets (assets that a company expects to use up or convert to cash within a year). It represents the $ amount of current assets a company has for every $1 of short-term debt. A high current ratio above 1.0 indicates that a company can meet its short-term obligations, while a low current ratio below 1.0 suggests difficulty.
Learn more at Investopediaopen_in_new
OptimizeRx’s Current Ratio of 15.44 is greater than its Industry Group of 1.69 (813.6% greater)
OptimizeRx’s Current Ratio of 15.44 is greater than its Major Industry Group of 1.69 (813.6% greater)
OptimizeRx’s Current Ratio of 15.44 is greater than its Sector of 1.59 (871.1% greater)
Derived from SEC.GOV filing dataopen_in_new
Value Analysis
PE ratio (price-to-earnings), measures a company’s stock price relative to its earnings per share. It helps investors evaluate whether its stock is overvalued or undervalued. A higher PE ratio indicates that investors are willing to pay more for a company’s earnings, while a lower PE ratio (above zero) suggests the company could be undervalued.
Learn more at Investopediaopen_in_new
Cannot compare a negative PE Ratio (0.2 & -0.08)
Cannot compare a negative PE Ratio (0.2 & -0.68)
Cannot compare a negative PE Ratio (0.2 & -0.29)
Derived from SEC.GOV filing dataopen_in_new
The PB ratio (price-to-book), measures a company’s stock price relative to its book value (net value of a company’s assets reported on its balance sheet, after subtracting debt) per share. It is used to evaluate a company’s valuation, with a lower PB ratio (above zero) indicating a lower valuation and a higher PB ratio suggesting overvaluation.
Learn more at Investopediaopen_in_new
OptimizeRx’s PB Ratio of 1.11 is lower than its Industry Group of 1.63 (-31.9% lower)
OptimizeRx’s PB Ratio of 1.11 is lower than its Major Industry Group of 2.08 (-46.6% lower)
OptimizeRx’s PB Ratio of 1.11 is lower than its Sector of 1.88 (-41.0% lower)
Derived from SEC.GOV filing dataopen_in_new
Efficiency Analysis
ROE (Return on Equity), is a financial ratio that measures a company’s profitability relative to its shareholders’ equity (the amount of value in a company that belongs to the people who own shares). It indicates how efficiently a company generates profits per unit of equity invested. A high ROE suggests effective use of equity, while a low ROE indicates inefficiency.
Learn more at Investopediaopen_in_new
OptimizeRx’s ROE of 5.63 is greater than its Industry Group of 0.01 (56200.0% greater)
OptimizeRx’s ROE of 5.63 is greater than its Major Industry Group of -0.06 (9483.3% greater)
OptimizeRx’s ROE of 5.63 is greater than its Sector of -0.04 (14175.0% greater)
Derived from SEC.GOV filing dataopen_in_new
ROCE (Return on Capital Employed), is a financial ratio that measures a company’s profitability relative to the amount of capital invested in its operations. It indicates how well a company is generating profits from its capital investments. A high ROCE suggests effective use of capital, while a low ROCE indicates inefficiency.
Learn more at Investopediaopen_in_new
OptimizeRx’s ROCE of -0.14 is lower than its Industry Group of 0.02 (-800.0% lower)
OptimizeRx’s ROCE of -0.14 is lower than its Major Industry Group of -0.03 (-366.7% lower)
OptimizeRx’s ROCE of -0.14 is lower than its Sector of -0.02 (-600.0% lower)
Derived from SEC.GOV filing dataopen_in_new